CRO EXPERIENCE · CLINICAL TRIAL EVIDENCE
IQVIA
IQVIA provides clinical research services, healthcare data analytics and technology to life sciences companies worldwide. Explore its recorded services and trial experience, with operational learnings where available.
1,387distinct trials
22recorded services
33trials with learnings
Clinical trial experience
Showing 20 of 1,387 trials · Latest update first
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Holdings Inc. — Investigator Site payments
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Limited — On site monitoring; Statistical analysis; Regulatory expertise; Medical expertise; Investigator recruitment; Project management; Safety reporting; Q/A auditing
- IQVIA RDS Hellas Single Member S.A — On site monitoring; Regulatory expertise; Safety reporting
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Laboratories Limited — Laboratory analysis
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Laboratories LLC — Laboratory analysis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — Safety reporting
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study enrolled 451 participants at 120 investigative sites in 24 countries from 24 April 2018 to 31 December 2025.
- Because of an unexpected slowing of the EFS rate, the pre-planned second interim IRF-EFS analysis was converted to the final IRF-EFS analysis, with longer follow-up than originally planned.
These findings describe the trial, not IQVIA’s performance or responsibility.
View recorded services & entities
- IQVIA Limited — On site monitoring
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Limited — Pharmacovigilance
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- A global amendment increased the planned eligible sample from 1500 to approximately 2510 because low global COVID-19 hospitalization and death rates reduced endpoint event rates.
- Rapid enrollment prevented the planned interim analysis after 65% of subjects completed Day 29 assessments; consequently, adolescent enrollment was not recommended and no pediatric subjects were enrolled.
- Of 218 screen failures, 177 were due to failure to meet entry criteria.
- Enrollment was concentrated in North America (1811/2285 subjects), whereas Europe enrolled 57 subjects, Asia 170 subjects, and other countries 247 subjects.
These findings describe the trial, not IQVIA’s performance or responsibility.
View recorded services & entities
- Iqvia Limited — On site monitoring; Statistical analysis; Regulatory expertise; Home nursing; Investigator recruitment; Project management; Data management; Safety reporting; Q/A auditing
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Laboratories Limited — Laboratory analysis
A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study with Long-Term Extension in Pediatric SMA Participants Previously Treated with Onasemnogene Abeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115.
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Laboratories Limited — DNA analyses
- IQVIA Limited — On site monitoring; Regulatory expertise; Site start-up and management, project & vendor management, medical monitoring.; Investigator recruitment
A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — Global CRO
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Inc. — On site monitoring; Statistical analysis; Medical writing; Regulatory expertise; Investigator recruitment; Data management; Safety reporting; Q/A auditing
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — On site monitoring; ECG analysis/review
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — EKG Provider; Monitoring
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures
Sponsor Sk Life Science Inc.
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- Iqvia Rds Ireland Limited — Pharmacovigilance
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — Central Laboratory; Laboratory analysis
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — Pharmacovigilance
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis, followed by an open label extension phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — Randomization of Patients and Management of drug supply logistics, dispensing and unblinding; Interactive response technologies (IRT); Clinical Trial Educator
An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the pediatric ORION-16 , ORION-13, ORION-20, or ORION-19 studies (VICTORION-PEDS-OLE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — On site monitoring; Management of drug supply logistics, dispensing, patient visit tracking
- IQVIA RDS Hellas Single Member S.A. — On site monitoring
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
View recorded services & entities
- IQVIA Limited — IMP label translation; Safety reporting
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not IQVIA’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish IQVIA’s responsibility.
Service synonyms are grouped; original wording and entity names remain in each trial. This pilot groups explicitly IQVIA-labelled names (43 variants). Legacy names such as Quintiles are excluded pending review. About IQVIA ↗
View recorded company names
- IQVIA
- IQVIA AG, Branch Basel
- IQVIA Clinical Trial Payments
- IQVIA Connected Devices
- IQVIA HELLAS S.A.
- IQVIA Inc
- IQVIA Laboratories
- IQVIA Laboratories (Q2 Solutions) Americas
- IQVIA Laboratories Argentina (CentraLab) Q2 Solutions – Affiliate/Partner Laboratory
- IQVIA Laboratories Brazil (DASA)
- IQVIA Laboratories India
- IQVIA Laboratories Japan (QJPN)
- IQVIA Laboratories LLC
- IQVIA Laboratories Ltd
- IQVIA Laboratories Ltd., UK
- IQVIA Labs Valencia
- IQVIA Limited
- IQVIA RDS & Integrated Services Belgium
- IQVIA RDS (India) Private Limited
- IQVIA RDS (Shanghai) Co. Ltd.
- IQVIA RDS East Asia Pte Ltd
- IQVIA RDS Hellas Single Member S.A
- IQVIA RDS Hellas Single Member S.A.
- IQVIA RDS Hellas, Single Member S.A.
- IQVIA RDS Ireland Limited
- IQVIA RDS Spain S.L.
- IQVIA RDS, Inc.
- IQVIA Uk Ltd ( IQVIA Connected Devices)
- Iqvia Biotech LLC
- Iqvia Biotech Limited
- Iqvia Holdings Inc.
- Iqvia Inc.
- Iqvia Laboratories Asia Pte. Ltd.
- Iqvia Laboratories Canada Inc.
- Iqvia Laboratories Limited
- Iqvia Limited
- Iqvia Pharma Inc.
- Iqvia Rds GmbH
- Iqvia Rds Inc.
- Iqvia Rds Ireland Limited
- Iqvia Rds Italy S.r.l.
- Iqvia Rds Spain S.L.
- Iqvia Solutions Italy S.r.l.